China is speeding up efforts to regulate medical devices even as it expands support for the domestic industry in a push that could come at the expense of multinational companies.

HONG KONG – With the release of first quarter earnings reports from three major Chinese biopharmaceutical companies, a variety of different opportunities and challenges in the mainland market were highlighted, as well as the growing importance of mergers and acquisition (M&A) to the bottom lines of companies in this increasingly competitive market.